Carmel, CA More Sad Alzheimer's Research News, This Time On Solanezumab : View From A Private Duty Caregiver
by Richard Kuehn on 08/26/12
Eli Lilly announced this week that it missed two key goals it had in the testing of a new treatment for Alzheimer's disease, although the drug (solanezumab) did show some potential for slowing the memory decline in patients with mild cases of it. "If that can be replicated, that is a major finding," William H. Thies, chief medical officer and scientific officer for the Alzheimer's Association told a reporter. "It's the first time we've been able to change the course of Alzheimer's disease or any part of Alzheimer's disease in people," he said. Still, the results were clearly not what was hoped for, and the struggle to find something to treat this incurable disease will go on. Regular readers of my blog know that both my father and my grandmother had Alzheimer's disease when they passed away. I am a big supporter of the Alzheimer's Association, which has a 24-hour help line at 800-272-3900. They are also the largest private supporter of Alzheimer's research in the United States. Please help them with their important mission if you can by clicking on this link for Family inHome Caregiving fundraising site for Alzheimer's Association.
